North America Endocrine Disruption Screening Market

Market Introduction

The North America endocrine disruption screening market has been segmented into the US, Canada, and Mexico. The US held the largest share of the North America endocrine disruption screening market in 2021. Increasing adoption of technological advancements in the screening of endocrine disruption chemicals and rising research and development activities are projected to accelerate the growth of the endocrine disruption screening market. Moreover, the presence of large healthcare businesses and the growing number of hormone related cancers in North America is propelling the market's expansion in this region.      

North America is highly affected due to the outbreak of the COVID-19. Countries such as the US and Canada reported the highest numbers of COVID-19 positive cases. The US registered highest number of deaths due to the COVID-19 pandemic. The chaotic situation was created in the various industry across the countries and increased the demand for diagnosis and screening devices. The life sciences segment thrives due to increased demand for in-vitro diagnostic products and rising research and development activities. Chronic diseases are common in patients at high risk of severe forms of COVID-19; however, other risk factors may also play a role. Environmental stresses, including as endocrine disrupting chemicals (EDCs), can aggravate the course of COVID-19 and contribute to the development of some chronic disorders. Several research studies have shown that patients with thyroid issues are more susceptible to the COVID 19 virus. The more severe the COVID-19, the lower the TSH and TT3 levels were, with statistical significance, according to a January 2021 research report titled "Thyroid Function Analysis in 50 Patients with COVID-19: A Retrospective Study." The severity of the condition was positively linked with the degree of declines in TSH and TT3 levels. As a result, alterations in serum TSH and TT3 levels are key symptoms of COVID-19 regimens.    

North America Endocrine Disruption Screening Strategic Insights

Strategic insights for the North America Endocrine Disruption Screening provides data-driven analysis of the industry landscape, including current trends, key players, and regional nuances. These insights offer actionable recommendations, enabling readers to differentiate themselves from competitors by identifying untapped segments or developing unique value propositions. Leveraging data analytics, these insights help industry players anticipate the market shifts, whether investors, manufacturers, or other stakeholders. A future-oriented perspective is essential, helping stakeholders anticipate market shifts and position themselves for long-term success in this dynamic region. Ultimately, effective strategic insights empower readers to make informed decisions that drive profitability and achieve their business objectives within the market.

North America Endocrine Disruption Screening Report Scope

North America Endocrine Disruption Screening Regional Insights

The geographic scope of the North America Endocrine Disruption Screening refers to the specific areas in which a business operates and competes. Understanding local distinctions, such as diverse consumer preferences (e.g., demand for specific plug types or battery backup durations), varying economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved areas or adapting their offerings to meet local demands. A clear market focus allows for more effective resource allocation, targeted marketing campaigns, and better positioning against local competitors, ultimately driving growth in those targeted areas.

The endocrine disruption screening market in North America is expected to grow from US$ 50,311.25 million in 2021 to US$ 61,319.50 million by 2028; it is estimated to grow at a CAGR of 2.9% from 2021 to 2028. Regulatory agencies throughout the world are grappling with the task of assessing the hazards and dangers to human and ecosystem health that may come from exposure to substances that disrupt the normal functioning of endocrine systems. The rapidly rising number of compounds in commerce, along with the dependence on conventional, expensive animal tests for hazard assessment – frequently with insufficient sensitivity to many critical processes of endocrine disruption – poses persistent problems for chemical management. As a result, there are only a few compounds for which there is enough evidence to determine whether there is endocrine toxicity, and hence only a few substances with full hazard categorization. To address this issue, regulatory assessment of endocrine disrupting chemicals (EDCs) is benefiting from a toxicology revolution focused on New Approach Methodologies (NAMs) to identify, prioritize, and assess the potential risks from chemical exposure using novel, more efficient, and mechanistically driven methodologies, and tools more rapidly.   

Key Market Segments

North America endocrine disruption screening market is segmented into assay type, application, source of waste, method, end-user, and country. The North America endocrine disruption screening market, by assay type, is bifurcated into in-vitro and in-vivo. The in-vitro segment led the market in 2021. By application, the North America endocrine disruption screening market is bifurcated into natural materials and synthetic materials. In 2021. The endocrine disruption screening market, by source of waste, is segmented into incineration and landfill, agricultural runoff, industrial and municipal effluents, pulp mill effluents, consumer products, and others. In 2021, the incineration and landfill segment held the largest share of the market. The North America endocrine disruption screening market, by method, is segmented into estrogen receptor (ER) transactivation, androgen receptor (AR) transactivation, androgen receptor (AR) modulation, estrogen receptor-alpha (ER) binding, estrogen receptor beta (ER) binding, androgen receptor (AR) binding, steroidogenesis, aromatase assay, and others. In 2021, the estrogen receptor (ER) transactivation segment held the largest share of the market. The North America endocrine disruption screening market, based on end use, is segmented into pharmaceutical and biopharmaceutical companies, cosmetics and household product companies, food industry, and chemical industry. In 2021, the pharmaceutical and biopharmaceutical companies segment held the largest share of the market. Based on country, the North America endocrine disruption screening market is segmented into US, Canada, and Mexico. US held the largest market share in 2020.

Major Sources and Companies Listed

A few major primary and secondary sources referred to for preparing this report on the Endocrine Disruption Screening market in North America are company websites, annual reports, financial reports, national government documents, and statistical database, among others. Major companies listed in the report are aALPHA ANALYTICAL, Inc.; Charles River Laboratories, Inc.; Creative Bioarray; Eurofins Scientific Ltd.; JRF Global; Mérieux NutriSciences; SGS SA; and Smithers.         

Reasons to buy report

• To understand the North America Endocrine Disruption Screening market landscape and identify market segments that are most likely to guarantee a strong return.
• Stay ahead of the race by comprehending the ever-changing competitive landscape for North America Endocrine Disruption Screening market.
• Efficiently plan M&A and partnership deals in North America Endocrine Disruption Screening market by identifying market segments with the most promising probable sales.
• Helps to take knowledgeable business decisions from perceptive and comprehensive analysis of market performance of various segment form North America Endocrine Disruption Screening market.
• Obtain market revenue forecast for market by various segments from 2021-2028 in North America region.

North America

Endocrine Disruption Screening Market

Segmentation

North America Endocrine Disruption Screening Market -

By Assay Type

• In-Vitro
• In-Vivo

North America Endocrine Disruption Screening Market - By

Application

• Natural Materials
• Synthetic Materials

North America Endocrine Disruption Screening Market - By – Sources of Waste

• Incineration and Landfill
• Agricultural Runoff
• Industrial and Municipal Effluents
• Pulp Mill Effluents
• Consumer Products
• Others

North America Endocrine Disruption Screening Market - By Method

• Estrogen Receptor (ER) Transactivation
• Androgen Receptor (AR) Transactivation
• Androgen Receptor (AR) Modulation
• Estrogen Receptor-Alpha (ER-alpha) Binding
• Estrogen Receptor Beta (ER-beta) Binding
• Androgen Receptor (AR) Binding
• Steroidogenesis
• Aromatase Assay
• Others

North America Endocrine Disruption Screening Market - By End User

• Pharmaceutical and Biopharmaceutical Companies
• Chemical Industry
• Food Industry
• Cosmetics and Household Product Companies

North America Endocrine Disruption Screening Market - By Country

• US
• Canada
• Mexico

North America Endocrine Disruption Screening Market - Company Profiles

• aALPHA ANALYTICAL, Inc.
• Charles River Laboratories, Inc.
• Creative Bioarray
• Eurofins Scientific Ltd.
• JRF Global
• Mérieux NutriSciences
• SGS SA
• Smithers